Cellomics has named William Sharp the vice president of business development, the company announced on June 24.
Sharp joins Cellomics with more than 20 years of industry experience in business development, sales, marketing, and general management, Cellomics said. Most recently, he served as vice president of business development with Gentra Systems. Prior to this, he spent more than six years with Life Technologies (Invitrogen).
According to an official statement, Sharp will now head up Cellomics’ business strategy, broadly characterized as making high-content screening, which the company invented, more widely available to life sciences researchers in industry and academics (see related story, this issue: GE Healthcare Licenses Cellomics’ Core IP For High-Content Screening Methods).
MultiCell Technologies has announced that Stephen Chang has joined the company’s board of directors.
As announced at the company’s June 16 shareholder’s meeting, Chang was nominated and unanimously elected by the board to serve as a director of the newly merged company and to act as a liaison between the board of directors and the scientific advisory board.
Chang is currently the CEO of Astral Therapeutics, and has served as the chief science officer and vice president of Canji/Schering Plough Research Institute. Prior to this, Chang was the director of research for Chiron Viagene and Chiron. Chang earned his PhD from the University of California, Irvine.
RNAi company Benitec has appointed Sally Brashears vice president of IP, Benitec said on June 18. Brashears, who has over 10 years of cell and molecular biology patent experience, has formerly held positions as a patent attorney with Moser, Patterson & Sheridan; as director of intellectual property for Clontech Laboratories and Perlagen Sciences; and as outside US patent counsel to the National Stem Cell Center in Melbourne, Australia.